Novel TLR7 Agonist Stimulates Activity of CIK/NK Immunological Effector Cells to Enhance Antitumor Cytotoxicity

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Mar 20

PMID 29552145

Citations 1

Authors

Dong Gao

Yongguang Cai

Yanyuan Chen

Wang Li

Chih-Chang Wei

Xiaoling Luo

Yuhuan Wang

Affiliations

Soon will be listed here.

Abstract

Toll-like receptor (TLR) 7/8 agonists have been applied in combination with chemo-, radio- or immunotherapy for lymphoma, and used as topical drugs for the treatment of viral skin lesions and skin tumors. In the present study, the role of an adenine analog, 9-(4-carboxyphenyl)-8-hydroxy-2-(2-methoxyethoxy)-adenine [termed Gao Dong (GD)], a novel TLR7 agonist, in the activation of cytokine-induced killer/natural killer (CIK/NK) cells was determined. The results of the present study indicated that GD was able to activate CIK/NK cells. The proportion of GD-induced CD3CD56 CIK and CD3CD56 NK cells was ~4% higher respectively compared with the control. Notably, combination therapy with CIK/NK cells stimulated by GD, markedly suppressed the proliferation of the chronic myelogenous leukemia K562 cell line. Following GD treatment, the cytotoxicity improved by ~25 and 21% when the effector/target ratio was 20:1 and 10:1, respectively. The results of the present study suggested a novel protocol for CIK/NK cell proliferation and revealed that GD may serve as a potent innate and adaptive immunomodulator in immunocyte culture.

Citing Articles

Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells.

Zhang C, Xiong X, Li Y, Huang K, Liu L, Peng X Oncol Lett. 2019; 18(6):6525-6535.

PMID: 31807172 PMC: 6876305. DOI: 10.3892/ol.2019.11020.

References

Pittari G, Filippini P, Gentilcore G, Grivel J, Rutella S . Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol. 2015; 6:230. PMC: 4429635. DOI: 10.3389/fimmu.2015.00230. View

Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N . A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2013; 34(2):194-203. DOI: 10.1007/s10875-013-9976-0. View

Lee M, Park C, Lee Y, Im S, Song S, Lee C . Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014; 37(9):1234-40. DOI: 10.1007/s12272-014-0379-4. View

Abrahamsen I, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord G . Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease. Haematologica. 2005; 90(1):86-93. View

Alvarnas J, Linn Y, Hope E, Negrin R . Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):216-22. DOI: 10.1053/bbmt.2001.v7.pm11349808. View

Dovedi S, Melis M, Wilkinson R, Adlard A, Stratford I, Honeychurch J . Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2012; 121(2):251-9. DOI: 10.1182/blood-2012-05-432393. View

Sakamoto N, Ishikawa T, Kokura S, Okayama T, Oka K, Ideno M . Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015; 13:277. PMC: 4548900. DOI: 10.1186/s12967-015-0632-8. View

Chung M, Park J, Bang S, Park S, Song S . Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother. 2014; 63(9):939-46. PMC: 11029701. DOI: 10.1007/s00262-014-1566-3. View

Schmeel F, Schmeel L, Gast S, Schmidt-Wolf I . Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci. 2014; 15(8):14632-48. PMC: 4159872. DOI: 10.3390/ijms150814632. View

10.

Zhou Z, Yu X, Zhang J, Tian Z, Zhang C . TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015; 369(2):298-306. DOI: 10.1016/j.canlet.2015.09.017. View

11.

Hoyle C, Bangs C, Chang P, Kamel O, Mehta B, Negrin R . Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998; 92(9):3318-27. View

12.

Xu K, Li C, Pan X, Du B . Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro. Int J Hematol. 2007; 86(1):84-90. DOI: 10.1532/IJH97.A10613. View

13.

Friedberg J, Kelly J, Neuberg D, Peterson D, Kutok J, Salloum R . Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009; 146(3):282-91. PMC: 2747261. DOI: 10.1111/j.1365-2141.2009.07773.x. View

14.

Richardt-Pargmann D, Wechsler M, Krieg A, Vollmer J, Jurk M . Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. Immunobiology. 2010; 216(1-2):12-23. PMC: 2964431. DOI: 10.1016/j.imbio.2010.03.011. View

15.

Deng Q, Bai X, Lv H, Xiao X, Zhao M, Li Y . Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways. Exp Ther Med. 2015; 9(4):1215-1222. PMC: 4353788. DOI: 10.3892/etm.2015.2264. View

16.

Schmidt-Wolf I, Negrin R, Kiem H, Blume K, Weissman I . Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174(1):139-49. PMC: 2118875. DOI: 10.1084/jem.174.1.139. View

17.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

18.

Perez-Martinez A, Fernandez L, Valentin J, Martinez-Romera I, Corral M, Ramirez M . A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy. 2015; 17(11):1594-603. DOI: 10.1016/j.jcyt.2015.07.011. View

19.

Gao D, Diao Y, Li W, Gao N, Liu Y, Wang Z . Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens. ChemMedChem. 2015; 10(6):977-80. DOI: 10.1002/cmdc.201500088. View

20.

Helms M, Prescher J, Cao Y, Schaffert S, Contag C . IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother. 2010; 59(9):1325-34. PMC: 4922493. DOI: 10.1007/s00262-010-0860-y. View